Cadrenal Therapeutics (CVKD) Short Interest Ratio & Short Volume

Short interest is the volume of Cadrenal Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 15th, investors have sold 23,900 shares of CVKD short. 5.48% of Cadrenal Therapeutics' shares are currently sold short. Learn More on Cadrenal Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.48% of Cadrenal Therapeutics' floating shares are currently sold short.

Cadrenal Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 23,900 shares, an increase of 32.8% from the previous total of 18,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Cadrenal Therapeutics currently has issued a total of 1,070,000 shares. Some of Cadrenal Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cadrenal Therapeutics currently has a public float of 435,900 shares.

5.48% of Cadrenal Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cadrenal Therapeutics: Mesoblast Limited (1.09%), Arcutis Biotherapeutics, Inc. (24.01%), Applied Therapeutics, Inc. (12.65%), CARGO Therapeutics, Inc. (17.19%), Phibro Animal Health Co. (1.94%), Phathom Pharmaceuticals, Inc. (29.47%), Cullinan Therapeutics, Inc. (23.23%), Rapport Therapeutics (10.68%), AnaptysBio, Inc. (23.16%), Pliant Therapeutics, Inc. (11.43%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks.

Short selling CVKD is an investing strategy that aims to generate trading profit from Cadrenal Therapeutics as its price is falling. CVKD shares are trading up $0.64 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cadrenal Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CVKD, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CVKD, twice per month. The most recent reporting period available is October, 15 2024.